Support for reproductive rights in the following legislation and government actions: H.R. 4104 / S. 2149, Health Equity and Access under the Law (HEAL) For Immigrant Families H.R. 4611 / S. 2377, Equal Access to Abortion Coverage in Health Insurance (EACH) Act H.R. 12 / S. 2150, Womens Health Protection Act (WHPA) H.R. 4516 / S. 2252, Saving Lives and Taxpayer Dollars Act H.R. 5202 / S. 1598, BABIES Act H.R. 8089 / S. 4186, Perinatal Workforce Act H.R. 5370 / S. 5296, Pathways to Health Careers Act H.R. 6238 / S. 3254, NIH IMPROVE Act H.R. 9712 / S. 4986, Mamas First Act H.R. 9941 / S. 5108, Right to IVF Act of 2026 H.R. 3202, MIDWIVES for Service Members Act of 2025 H.R. 4150, Advancing Maternal Health Equity Under Medicaid Act H.R. 9842, State Offices of Womens Health Support and Expansion Act H.R. 10600, Abortion is Health Care Everywhere Act of 2026 H.R. 9753, Fertility Cost Relief Act H.R. 211, Equal Access to Contraception for Veterans Act H.Res. 1389, Expressing the sense of the House of Representatives that the monitoring and regulation of water systems not be weaponized for the purposes of surveilling, tracking, or detecting use of, stigmatizing, and further restricting access to medication abortion care. Advocating for the use of science and accurate data to support decision-making in government policy with respect to mifepristone Providing feedback about provisions impacting reproductive rights in the following legislation: H.R. 7973, Momnibus Act S. 3097, Health Information Privacy Reform Act Opposing provisions impacting reproductive rights in the following legislation: H.R. 1, One Big Beautiful Bill Act, Section 71113 "Federal Payments to Prohibited Entities. Section 71113 bars Essential Community Providers whose Medicaid reimbursements exceeded $800,000 in FY23 from receiving federal funds if they are primarily engaged in providing family planning or related reproductive health services and provide abortion care beyond the exceptions in the Hyde Amendment. H.R. 8469, Making appropriations for military construction, the Department of Veterans Affairs, and related agencies for the fiscal year ending September 30, 2027, and for other purposes. Opposing language titled Reproductive Health Services in Title II of the report accompanying the bill regarding the funding for abortion care for veterans. H.R. 9495, Making appropriations for the Department of Defense for the fiscal year ending September 30, 2027, and for other purposes. Section 8153 prohibiting the use of human fetal tissue for research if the tissue is obtained pursuant to an abortion. Section 8158 prohibiting the use of government funds for servicemembers to travel for abortion care. Opposing all provisions in the following legislation or administrative actions: H.R. 589, FACE Act Repeal Act of 2025 "Anti-Weaponization Fund that could benefit individuals convicted of violating the FACE Act. Opposing the nomination of: Todd Blanche, Attorney General, PN1078 Heidi Overton, Commissioner of the Food and Drug Administration (FDA), PN1273-17
Filing · LD-2 quarterly report
Q3 report
Reporting period
3rd Quarter 2026
July 1 - Sep 30 · Posted Oct 20, 2026
Expenses
$50,000
What this organization spent lobbying with its own staff.
Reported using IRS section 6033(b)(8) definitions (method B): the three
LDA methods count different costs, so an expenses figure is
not comparable across filers that used different ones.
Client based in
New York
Government bodies contacted
2
Lobbying activity
1
Bills named in this filing
33